File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/S0167-8140(12)70832-0
- Find via
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: The battle against nasopharyngeal cancer
Title | The battle against nasopharyngeal cancer |
---|---|
Authors | |
Issue Date | 2012 |
Citation | The 31st Annual Meeting of the European Society for Therapeutic Radiology and Oncology (ESTRO-31), Barcelona, Spain, 9-13 May 2012. In Radiotherapy and Oncology, 2012, v. 103 suppl. 1, p. S198, abstract SP-0493 How to Cite? |
Abstract | Nasopharyngeal cancer (NPC) is one of most difficult cancers to treat
because of its highly malignant natural behavior and its anatomical
proximity to critical structures. This cancer was invariably lethal
before the advent of megavoltage radiotherapy (RT). Dr John Ho from
Hong Kong was the leading pioneer in the battle against NPC. His
foresight in identification of environmental carcinogens, the need for
accurate prognostication by customized staging system, and the
design of radiotherapy technique set the foundation for our
understanding of this peculiar disease.
Over the past 30 years, clinical oncologists from Hong Kong have made
concerted efforts to continue this pursue. The statistics from the
Hong Kong Cancer Registry from 1980 to 2009 showed that the age
standardized incidence rate of NPC has decreased by 51% for male and
59% for female populations. Together with improving treatment
results, the corresponding agestandardized mortality rate has
decreased by 60% and 67%, respectively.
With advances of the technology of both diagnostic imaging and RT,
together with development of concurrent cisplatinbased
chemotherapy for locoregionally advanced NPC, retrospective
analyses of 1374 consecutive patients treated at our institute (Pamela
Youde Nethersole Eastern Hospital) from 1994 to 2007 showed
significant improvement in cancerspecific survival from 79% in the
era of 2dimensional conventional RT, 81% in the era of 3dimensional
conformal RT, to 88% in the recent era of intensitymodulated RT.
We have indeed achieved gratifying progress in this difficult battle
against NPC, but there is no ground for complacency. Many serious
problems remain to be solved: this cancer remains one of the most
prevalent cancers in South East Asia, majority of patients still present
with advanced disease, distant failure remains a key failure despite
chemotherapy, late toxicities still seriously affects survivors’ quality
of life. Furthermore, more accurate prognostic and predictive factors
are needed for working towards the ideal goal of personalized
medicine. Concerted efforts by all are needed to realize the dream of
controlling this nasty cancer within our life time. |
Description | Award Lecture for Honorary Member of ESTRO |
Persistent Identifier | http://hdl.handle.net/10722/220915 |
ISSN | 2023 Impact Factor: 4.9 2023 SCImago Journal Rankings: 1.702 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, WMA | - |
dc.date.accessioned | 2015-10-22T09:14:33Z | - |
dc.date.available | 2015-10-22T09:14:33Z | - |
dc.date.issued | 2012 | - |
dc.identifier.citation | The 31st Annual Meeting of the European Society for Therapeutic Radiology and Oncology (ESTRO-31), Barcelona, Spain, 9-13 May 2012. In Radiotherapy and Oncology, 2012, v. 103 suppl. 1, p. S198, abstract SP-0493 | - |
dc.identifier.issn | 0167-8140 | - |
dc.identifier.uri | http://hdl.handle.net/10722/220915 | - |
dc.description | Award Lecture for Honorary Member of ESTRO | - |
dc.description.abstract | Nasopharyngeal cancer (NPC) is one of most difficult cancers to treat because of its highly malignant natural behavior and its anatomical proximity to critical structures. This cancer was invariably lethal before the advent of megavoltage radiotherapy (RT). Dr John Ho from Hong Kong was the leading pioneer in the battle against NPC. His foresight in identification of environmental carcinogens, the need for accurate prognostication by customized staging system, and the design of radiotherapy technique set the foundation for our understanding of this peculiar disease. Over the past 30 years, clinical oncologists from Hong Kong have made concerted efforts to continue this pursue. The statistics from the Hong Kong Cancer Registry from 1980 to 2009 showed that the age standardized incidence rate of NPC has decreased by 51% for male and 59% for female populations. Together with improving treatment results, the corresponding agestandardized mortality rate has decreased by 60% and 67%, respectively. With advances of the technology of both diagnostic imaging and RT, together with development of concurrent cisplatinbased chemotherapy for locoregionally advanced NPC, retrospective analyses of 1374 consecutive patients treated at our institute (Pamela Youde Nethersole Eastern Hospital) from 1994 to 2007 showed significant improvement in cancerspecific survival from 79% in the era of 2dimensional conventional RT, 81% in the era of 3dimensional conformal RT, to 88% in the recent era of intensitymodulated RT. We have indeed achieved gratifying progress in this difficult battle against NPC, but there is no ground for complacency. Many serious problems remain to be solved: this cancer remains one of the most prevalent cancers in South East Asia, majority of patients still present with advanced disease, distant failure remains a key failure despite chemotherapy, late toxicities still seriously affects survivors’ quality of life. Furthermore, more accurate prognostic and predictive factors are needed for working towards the ideal goal of personalized medicine. Concerted efforts by all are needed to realize the dream of controlling this nasty cancer within our life time. | - |
dc.language | eng | - |
dc.relation.ispartof | Radiotherapy & Oncology | - |
dc.relation.ispartof | The 31st Annual Meeting of the European Society for Therapeutic Radiology and Oncology (ESTRO 31), 2012 | - |
dc.title | The battle against nasopharyngeal cancer | - |
dc.type | Conference_Paper | - |
dc.identifier.email | Lee, WMA: awmlee@hkucc.hku.hk | - |
dc.identifier.authority | Lee, WMA=rp02056 | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1016/S0167-8140(12)70832-0 | - |
dc.identifier.hkuros | 266848 | - |
dc.identifier.volume | 103 | - |
dc.identifier.issue | suppl. 1 | - |
dc.identifier.spage | S198, abstract SP-0493 | - |
dc.identifier.epage | S198, abstract SP-0493 | - |
dc.identifier.issnl | 0167-8140 | - |